Home > Insider Trading > Filing (0001127602-21-017677)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
313143	Haemonetics Corp	HAE	Surgical & Medical Instruments & Apparatus (3841)	042882273

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1682069	Mr. P. William Burke	125 Summer Street Boston MA 02110	Evp, Chief Financial Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2021-05-18	6,628	$0.00	17,746	No	4	A	Direct
Common Stock	Acquisiton	2021-05-18	17,677	$0.00	35,423	No	4	A	Direct
Common Stock	Disposition	2021-05-19	238	$55.19	35,185	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	A	Direct
No	4	A	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Non-qualified Stock Option (Right to Buy)	Acquisiton	2021-05-18	17,933	$0.00	17,933	$56.57

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
17,933		2028-05-18	No	4	A	Direct

Footnotes

The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest in annual increments of 25% beginning on the first anniversary of the date of grant.
Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.
This number includes unvested RSUs previously reported.
The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest in annual increments of 50% beginning on the first anniversary of the date of grant.
Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2019 Long Term Incentive Compensation Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
Option vests in annual increments of 25% beginning on the first anniversary of the date of grant.